THX Pharma (ALTHX.PA)
THX Pharma operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, AR, FR. The stock last traded at $4.38, down 2.56% on the session, giving a market capitalisation of $63.2M. Its beta of 1.52 implies it has historically moved more than the broad market.
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
THX Pharma is most often compared with the following Healthcare names: